This report provides a comprehensive breakdown of clinical trial costs by phase and therapeutic area, with a focus on key cost components including per-patient costs, total costs, CRO fees, and service-specific expenses.
This report provides a comprehensive breakdown of clinical trial costs by phase and therapeutic area, with a focus on key cost components including per-patient costs, total costs, CRO fees, and service-specific expenses.Clinical trials represent one of the most resource-intensive stages in the lifecycle of a drug, biologic, or device.
For sponsors, understanding the cost structure of trials by phase, therapeutic area, and CRO services is essential to plan budgets, engage investors, and select outsourcing partners strategically. This detailed analysis consolidates public data, industry benchmarks, and Contract Research Organization(CRO) cost models to offer actionable insights for sponsors.
Clinical trial costs increase with each progressive phase of development, with Phase III trials being the most expensive in absolute terms. However, Phase I/II trials often incur the highest per-patient costs due to intensive monitoring and smaller cohort sizes. These early-phase trials require specialized clinical sites, rigorous safety assessments, and frequent lab tests or imaging, all of which contribute to the higher per-subject expense.
Trial Phase | Avg. Total Cost (USD) | Avg. Enrollment | Avg. Cost per Patient (USD) |
Phase I | $5.26 million | 39 | $136,783 |
Phase I/II | $10.79 million | 71 | $155,340 |
Phase II | $18.49 million | 143 | $129,777 |
Phase II/III | $42.10 million | 300 | $140,344 |
Phase III | $52.84 million | 479 | $113,030 |
Key Points:
Therapeutic area significantly influences cost, with oncology & neurology ranking among the most expensive. Factors include recruitment difficulty, complex endpoints, longer timelines, & advanced diagnostics.Additionally, these trials often require highly specialized investigators, intensive monitoring, & frequent imaging or biomarker assessments.
In oncology, the need for precision medicine approaches & molecular profiling further drives up costs. Neurology trials, especially those targeting neurodegenerative diseases, face high screen failure rates & necessitate long-term follow-ups to measure efficacy outcomes, adding to both operational complexity & financial burden.
Therapeutic Area | Phase I ($) | Phase II ($) | Phase III ($) |
Oncology | 152,000 | 130,500 | 124,800 |
Neurology | 158,000 | 139,200 | 122,105 |
Cardiovascular | 135,000 | 127,000 | 121,000 |
Infectious Diseases | 122,000 | 119,500 | 111,100 |
Rheumatoid Arthritis | 145,300 | 128,000 | 121,383 |
Endocrine (e.g. T2D) | 131,000 | 124,500 | 119,241 |
Respiratory | 127,800 | 121,200 | 116,940 |
Dermatology | 110,000 | 104,000 | 99,800 |
Psychiatry | 139,000 | 125,700 | 118,000 |
Key Points:
Contract Research Organizations (CROs) are responsible for executing up to 65% of a trial’s scope. Understanding the cost structure of CRO services is critical for budgeting and negotiation.These costs typically encompass project management, clinical monitoring, site management, data management, biostatistics, regulatory support, and medical writing. Factors influencing CRO pricing include trial phase, therapeutic area, geographic reach, enrollment timelines, and the complexity of study endpoints.
Additionally, sponsor-CRO collaboration models—such as full-service outsourcing, functional service provision (FSP), or hybrid models—can significantly affect overall costs and operational efficiency. Early clarity on deliverables, timelines,& change-order policies helps prevent budget overruns & ensures transparency throughout the clinical development process.
CRO Service Component | % of CRO Budget | Notes & Examples |
Clinical Procedures | 15–22% | Labs, imaging, biopsies, ECGs |
Site Monitoring | 9–14% | On-site visits, data verification |
Project Management | 8–12% | Coordination, reporting, oversight |
Data Management | 5–10% | CRF setup, query resolution, database lock |
Biostatistics | 2–5% | Analysis plan, interim/final analysis |
Regulatory Affairs | 5–8% | IND/CTA submissions, IRB communication |
Patient Recruitment | 2–5% | Outreach campaigns, patient databases |
Medical Monitoring | 3–6% | AE/SAE review, medical oversight |
Quality Assurance (QA) | 3–5% | GCP audits, compliance verification |
Legal, Contracts, Insurance | 10–15% | Site contracts, trial insurance |
Key Points:
Clinical trial costs are influenced by numerous factors: trial phase, indication, procedures, and CRO services. Sponsors should arm themselves with granular cost data and service benchmarks to make informed decisions. By aligning trial design with cost expectations and leveraging smart outsourcing, sponsors can accelerate timelines and control budgets without compromising data quality.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
